Experiences and perspectives of cancer stakeholders regarding COVID-19 vaccination

被引:4
作者
Bartley, Nicci [1 ]
Havard, Polly [1 ]
Butow, Phyllis [1 ]
Shaw, Joanne [1 ]
机构
[1] Univ Sydney, Fac Sci, Sch Psychol, Psychooncol Cooperat Res Grp, Level 6 North Lifehouse,C39Z, Sydney, NSW 2006, Australia
关键词
cancer; COVID-19; qualitative; stakeholder perspective; vaccine; ITALY EARLY DATA; 1ST REPORT; REFUSAL;
D O I
10.1111/ajco.13808
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim The risk of dying from COVID-19 is higher for those who are older, immune-compromised, or chronically ill. Vaccines are an effective strategy in reducing mortality and morbidity from COVID-19. However, for COVID-19 vaccination programs to reach full potential, vaccines must be taken up by those at greatest risk, such as cancer patients. Understanding the perspectives of all stakeholders involved in cancer patient COVID-19 vaccine uptake will be critical to ensuring appropriate support, and information is provided to facilitate vaccination. The aim of this research was to explore the longitudinal views of cancer stakeholders regarding COVID-19 vaccination. Methods Semistructured interviews were conducted with cancer patients (n = 23), family members (n = 10), cancer health professionals (n = 19), and representatives of cancer nongovernment organizations (n = 7) across Australia 6 and 12 months postrecruitment. Transcripts were thematically analyzed, using an inductive approach. Results All stakeholder groups expressed mostly positive attitudes toward COVID-19 vaccination, with the following key themes identified: (1) high motivation-vaccination perceived as offering health protection and hope; (2) hesitancy-concern about vaccine hesitancy among the general population, with a minority hesitant themselves; (3) confusion and frustration-regarding the vaccine rollout and patient eligibility; (4) uncertainty-about vaccination in the context of cancer; (5) access to vaccination; and (6) desire for expert individualized advice-on vaccine interaction with cancer treatments. Conclusion These findings highlight the COVID-19 vaccine concerns and information needs of cancer stakeholders. Policymakers need to provide clear tailored information regarding vaccine eligibility, accessibility, benefits, and risks to facilitate vaccine uptake.
引用
收藏
页码:234 / 242
页数:9
相关论文
共 41 条
[1]  
[Anonymous], 2021, PHAS 1B COVID 19 VAC
[2]  
[Anonymous], 2021, Centers for Disease Control and Prevention Diabetes Prevention Recognition Program Standards and Operating Procedures
[3]  
[Anonymous], 2021, COVID 19 VACC ROLL T
[4]  
Australian Bureau of Statistics, 2020, COVID 19 MORT
[5]  
Australian Government Department of Health, 2021, COVID 19 VACC DAIL R
[6]  
Australian Government Department of Health, 2021, COR COVID 19 CAS NUM
[7]  
Australian Government Department of Health, 2021, COVID 19 VACC ROLL U
[8]  
Australian New Zealand Clinical Trials Registry, 2021, SARS COV 2 POSTCOVID
[9]   Acceptance of SARS-CoV-2 vaccination among French patients with cancer: a cross-sectional survey [J].
Barriere, J. ;
Gal, J. ;
Hoch, B. ;
Cassuto, O. ;
Leysalle, A. ;
Chamorey, E. ;
Borchiellini, D. .
ANNALS OF ONCOLOGY, 2021, 32 (05) :673-674
[10]   Attitudes of Patients with Cancer towards Vaccinations-Results of Online Survey with Special Focus on the Vaccination against COVID-19 [J].
Brodziak, Anna ;
Sigorski, Dawid ;
Osmola, Malgorzata ;
Wilk, Michal ;
Gawlik-Urban, Angelika ;
Kiszka, Joanna ;
Machulska-Ciuraj, Katarzyna ;
Sobczuk, Pawel .
VACCINES, 2021, 9 (05)